1. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.
- Author
-
Levy, Ilana, Lavi, Avital, Zimran, Eran, Grisariu, Sigal, Aumann, Shlomzion, Itchaki, Gilad, Berger, Tamar, Raanani, Pia, Harel, Reut, Aviv, Ariel, Lavi, Noa, Zuckerman, Tsila, Shvidel, Lev, Jarchowsky, Osnat, Ellis, Martin, Herzog Tzarfati, Katrin, Koren-Michowitz, Maya, Sherf, Yehonatan, Levi, Itai, and Sofer, Orit
- Subjects
COVID-19 ,HEMATOLOGIC malignancies ,CONVALESCENT plasma ,TREATMENT effectiveness ,RETROSPECTIVE studies - Abstract
This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory data from haemato-oncological patients diagnosed with COVID-19 from 16 medical centers were centrally reported. Multivariate regression analyses were used to determine variables associated with severe disease, hospitalization, and mortality. In total, 313 patients were included: 103 (35.7%) developed severe/critical respiratory infection, 178 (61.4%) were hospitalized, and 60 (20.0%) died. Age > 70 years was associated with severe/critical disease (p = 0.036) and mortality (p = 0.023), hypertension with severe/critical disease (p = 0.046) and hospitalization (p = 0.001), active haemato-oncological treatment with hospitalization (p = 0.009), and remdesivir treatment was associated with decreased mortality (p = 0.021). Convalescent plasma, enoxaparin, and corticosteroids resulted in no clinical benefit. In conclusion, COVID-19 infection seems particularly severe in patients with hematological malignancies, and of all examined therapies, remdesivir appears to be the most effective. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF